Cancer Nanomedicine

© 2020 by the authors; CC BY-NC-ND license

antibody drug conjugate (ADC); PD-L1; tumor spheroid disruption; immune modulation; doxorubicin; graphene oxide; adsorption; cathepsin D; cathepsin L; anti-metastatic enzyme cancer therapy; nanoparticles; targeted delivery system; siRNA; osteopontin; mammary carcinoma; mesenchymal stem cells (MSCs); TAT peptide; PLGA; paclitaxel; nano-engineered MSCs; orthotopic lung tumor model; intracranial glioma; immunotherapy; CPMV; viral nanoparticles; in situ vaccine; albumin nanoparticles; microbubble; ultrasound; theranostics; hepatocellular carcinoma; VX2 tumor; intra-arterial chemotherapy; lung cancer; nanomedicine; theranostics; clinical status; cancer therapy; breast cancer; siRNA; cell signaling; active targeting; passive targeting; EPR effect; oncogenes; nanoparticles; nanomedicine; nanoparticle; drug delivery; ligand; active targeting; tumor targeting; biodistribution; Mesoporous silica nanoparticle; drug delivery system; target treatment; lanthanide metal; TAT peptide; hyaluronic acid; hyaluronidase; nanoparticles; drug combination; paclitaxel; everolimus; dual-targeting; breast cancer; graphene oxide; magnetic nanoparticles; monoclonal antibodies; tumor targeting; nanostructured lipid carrier; platelet membrane; biomimicry; paclitaxel; plasmonic photothermal therapy; gold nanorods; surgery; bleeding; dogs; cats; breast cancer; nanomedicine; drug delivery; stimuli-responsive; DOX; SN38; CSCs; single-walled carbon nanotubes; chirality separation; NASH; drug-gene delivery; near IR hyperspectral imaging; plasmonics; nanomedicine; theranostics; copper; VEGF; glioblastoma; differentiated neuroblastoma; peptidomimetics; real-time quantitative polymerase chain reaction (qPCR); actin; nanoparticles; combinatorial therapy; anticancer and antibacterial activity; temoporfin; drug-in-cyclodextrin-in-liposome; hybrid nanoparticles; multicellular tumor spheroids; cyclodextrins; photodynamic therapy article; yet reasonably common within the subject discipline; antitumor strategy; biomimetic core–shell nanoparticles; NK cell-derived exosomes; drug delivery system; folate receptor; albumin nanoparticle; microfluidic; cabazitaxel; polydopamine nanoparticles; size; cytotoxicity; iron affinity; doxorubicin; nanomedicine; FA-DABA-SMA; self-assembly; oncogenic proteins; intracellular disruption; folic receptor alpha; active targeting; drug delivery; pancreatic cancer; parvifloron D; nanoparticles; albumin; erlotinib; photodynamic therapy; lipid nanoparticles; drug delivery system; tumor vectorization; verteporfin; ovarian carcinomatosis; spheroids; nanomedicine; nanoparticles; integrin; RGD peptide; active targeting; cancer diagnosis; drug delivery; radiotherapy; hyperthermia therapy; biomimetic; nanocarrier; membrane-wrapped; cancer; targeted delivery; drug delivery; immunotherapy; photothermal therapy; photodynamic therapy; imaging; cancer nanomedicine; EPR effect; tumor microenvironment; nanoparticles; nano–bio interactions; clinical translation; magnetic nanowires; cancer; magnetic hyperthermia; magnetic actuation; magnetic drug targeting; titanate nanotubes; gold nanoparticles; vectorization; nanocarrier; colloidal stability; docetaxel; cytotoxicity; biodistribution; radiotherapy; prostate cancer; nanoparticles; mangiferin; anti-topoisomerase activity; cytotoxicity; extracellular vesicles; exosomes; chemico-physical functionalization; loading; cancer; nanomedicine; translational medicine; nanotechnology: bioengineering; anacardic acid; mitoxantrone; targeted drug delivery; liposomes; melanoma; apoptosis; ascorbic acid; angiogenesis; epithelial-to-mesenchymal transition; hypoxia; immunosuppression; metabolism; nanoparticle; nanotherapeutics; tumour microenvironment; DNA origami; liposome; breast cancer; remote loading; doxorubicin; acute toxicity; organoids; magnetic silica-coated iron oxide nanochains; nanoparticles; photothermal treatment; hyperthermia; cancer; collagen; cellular microenvironment; lymphadenectomy; magnetometer; prostate cancer; sentinel lymph node dissection; SPION; superparamagnetic iron oxide nanoparticles; Vδ2 T cells; zoledronic acid; polymeric nanoconstruct; anti-tumor immunity; colorectal carcinoma; β-cyclodextrin nanosponges; doxorubicin; breast cancer; BALB-neuT mice; EPR effect; brain tumours; glioma; blood brain barrier; drug delivery; nanomedicine; polymeric nanoparticles; PEGylation; dioleoylphosphatidylethanolamine; liposomes; poly(hydroxyethyl acrylate-co-allyl methyl sulfide) copolymer; folate; oxidation-sensitive release; doxorubicin; cellular interaction; in vitro anti-cancer activity; triple negative breast cancer; organotin; mesoporous silica nanoparticles; MDA-MB-231; theranostic nanomaterials; nanobiotechnology; molecular imaging; nanosystems; drug delivery; nanomicelles; ovarian cancer; tumour targeting; chemotherapeutics; riboflavin; vitamin B2; targeted drug delivery; active targeting; theranostics; nanomedicines; molecular imaging; nanoparticle; secondary structure; mixed micelle; pH responsive; drug delivery system; nanomedicine; nanoparticle; targeted therapy; anti-cancer; shear stress; flow; in vitro; cancer nanomedicine; therapeutics; diagnostics; imaging; theranostics; Immunotherapy; tumour microenvironment